The fact that conventional medicine is currently still unable to effectively treat and cure cancer is quite discouraging. Sadly, while sudden and acute diseases, like ictus or infarct, objectively leave little time for effective treatment, slowly growing illnesses like tumors demonstrate that modern therapies are still of little help.

The increasing number of tumor cases and the death rate reported every year (almost 300,000 in Italy), clearly indicate that current chemotherapy protocols are inadequate.
Tumor etiopathogenesis has not been fully explained yet, although manifold causes of tumor onset and proliferation are known.
Conventional cytotoxic and cytolytic therapies do not eradicate the agents responsible for tumor onset, but merely cause tumor cells to die.
However, some tumor cells always survive and become drug resistant, as they “adjust” to heavy and prolonged chemotherapy treatments and give rise to stronger tumor cell populations.
Sadly, the side effects of chemotherapy are known to adversely impact the immune system, as well as trophism and integrity of biological terrain, which are key to effectively defend the body from tumor aggression.
Other negative effects of chemotherapy include a considerable increase in free radicals – known to be carcinogenic factors – and the induction of cell mutations that are potentially cancerous.

The failure of cancer research campaigns like the National Cancer Act – funded with unprecedented allocations and signed by President Nixon on Dec. 23, 1971 – was compared by the American press to the devastating outcome of the Vietnam war.
Such failure, after several announced medical breakthroughs in the fight against cancer, leveled harsh criticism and eventually led the American press to define the outcome of the war on cancer as the “Vietnam war of medicine””.

In Ralph Moss’ opinion “the direction of cancer management appears to be shaped by those forces financially interested in the outcome of the problem”. He tells of the enormous financial and political corruption in the "cancer establishment" and indicates that the motivating forces in cancer research and treatment in the United States are often power and money, and not the cure of cancer patients. The funds for cancer research are allocated by the National Institute of Health. All legislation aims at concentrating power in the hands of a few and increasing a conservatory attitude in respect of new therapies.

The fact that surgery -which plays a major role in cancer treatment - tends to be radical and to remove all cancer localizations as much as possible, is seldom reckoned as an indication that effective cancer treatment and cure are not yet ensured by conventional methods, e.g. chemotherapy. If this was the case, there would be no need for extended and mutilating surgical interventions.
Moreover, any tumor should always be examined and considered as a systemic disease the onset of which has been caused by a biological and physiological distress or imbalance. This holds true even when a single tumor lesion is detected, which should therefore be viewed as the maximum concentration in one point of cancer cells that are potentially ubiquitous. Therefore, rational and causal treatment should aim at restoring biological and physiological balance on the one hand, and eradicating identified causal factors on the other.
Molecular biology is an essential component in the fight against cancer and thinking that there exists a single active ingredient capable of defeating cancer is naïve because of the many etiopathogenic causes involved.
Conversely, a multi-therapy like the Di Bella Method enables to safeguard the biological terrain, strengthen the body’s natural defense mechanisms and counter tumor growth and proliferation by inhibiting growth factors.
Biological and physiological balance may be restored by administering retinoids, Vitamins E, C, D3 and melatonin. These drugs strengthen the physiological (differentiated) cell growth of healthy tissues as opposed to neoplastic ones, and exert activity which is anti-oxidant, anti-free radicals, pro-differentiating (e.g. they convert tumor or undifferentiated cells back to normal cells) and pro-apoptotic (e.g. they cause tumor cell death without being cytotoxic).
The activity exerted is also immunostimulant, anti-proliferative, anti-metastatic and anti-angiogenic, and these drugs become even more effective inhibitors of growth factors if combined with other drugs like somatostatine and bromocriptine-cabergoline.
Such inhibitors act not only on GH, recognized by international literature as the primary carcinogenic factor, but also on many other important growth factors, like somatomedine, IGF I-II, EGF, FGF, NGF, prolactin, hPL, TGF-α and -β, PDGF and VEGF, that play a major role in cancer development, as much is more and more scientifically evidenced.